Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;17(12):1153-1168.
doi: 10.1016/j.autrev.2018.05.012. Epub 2018 Oct 12.

HIBISCUS: Hydroxychloroquine for the Secondary Prevention of Thrombotic and Obstetrical Events in Primary Antiphospholipid Syndrome

Cristina Belizna  1 Francesca Pregnolato  2 Sebastien Abad  3 Jaume Alijotas-Reig  4 Howard Amital  5 Zahir Amoura  6 Laura Andreoli  7 Emmanuel Andres  8 Achile Aouba  9 Sule Apras Bilgen  10 Laurent Arnaud  11 Boris Bienvenu  12 Viktoria Bitsadze  13 Patrick Blanco  14 Miri Blank  5 Maria Orietta Borghi  2 Antonia Caligaro  15 Elisabeta Candrea  16 Valentina Canti  17 Laurent Chiche  18 Jean Marie Chretien  19 Jan Willem Cohen Tervaert  20 Laura Damian  21 Teresa Delross  15 Emmanuelle Dernis  22 Katrien Devreese  23 Aleksandra Djokovic  24 Enrique Esteve-Valverde  25 Maria Favaro  15 Céline Fassot  26 Raquel Ferrer-Oliveras  27 Alban Godon  28 Mohamed Hamidou  29 Milena Hasan  30 Daniel Henrion  26 Bernard Imbert  31 Pierre Yves Jeandel  32 Pascale Jeannin  28 Patrick Jego  33 Noemie Jourde-Chiche  34 Jamilya Khizroeva  13 Olivier Lambotte  35 Cédric Landron  36 Jose Omar Latino  37 Estibaliz Lazaro  38 Karina de Leeuw  39 Thomas Le Gallou  33 Levent Kiliç  10 Maarten Limper  40 Laurent Loufrani  26 Romain Lubin  26 Nadine Magy-Bertrand  41 Guillaume Mahe  42 Alexander Makatsariya  13 Thierry Martin  43 Christian Muchardt  44 Gyorgy Nagy  45 Loukman Omarjee  42 Pieter Van Paasen  46 Gilles Pernod  47 Florence Perrinet  48 Gilberto Pïres Rosa  49 Marc Antoine Pistorius  50 Amelia Ruffatti  15 Fatma Said  51 Patrick Saulnier  19 Damien Sene  52 Loic Sentilhes  53 Ova Shovman  5 Jean Sibilia  11 Crina Sinescu  54 Natasa Stanisavljevic  24 Ljudmila Stojanovich  24 Lai Shan Tam  55 Angela Tincani  7 Fréderic Tollis  56 Sebastian Udry  37 Marie Noelle Ungeheuer  57 Mathilde Versini  58 Ricard Cervera  59 Pier Luigi Meroni  2
Affiliations
Review

HIBISCUS: Hydroxychloroquine for the Secondary Prevention of Thrombotic and Obstetrical Events in Primary Antiphospholipid Syndrome

Cristina Belizna et al. Autoimmun Rev. .

Abstract

The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.

Keywords: Antiphospholipid syndrome; Hydroxychloroquine; Primary antiphospholipid syndrome; Secondary prevention.

Similar articles

See all similar articles

Cited by 2 articles

Substances

Feedback